


Newsletter

by SRS LEGAL

● LIFE SCIENCES & HEALTHCARE



DRAGHI REPORT AND THE 23ANDME CASE

Draghi Report:
"The future of European competitiveness",
September 2024 - The pharmaceutical
sector.

The Draghi report by former Italian Prime Minister and ECB President Mario Draghi was published on 9 September. The report identifies 10 key sectors of the European Union's economy and how they can achieve the level of competitiveness that the EU needs in order to close the gap with the development of the North American economy. The pharmaceutical sector is one of these.

The Draghi report envisages three main blocks of measures for the pharmaceutical sector to grow sustainably, to be attractive and, as intended, competitive.

Measures for the pharmaceutical sector:

1) The need to encourage R&D, which requires an increase in EU public investment, while also focusing on private investment. For this to happen, there needs to be adequate incentives and an efficient and clearer regulatory framework, so that inequalities between member states can be reduced and perhaps eliminated.



2) In conjunction with the point above, the second block of measures focuses on the need to overcome the problems that have already been identified in terms of **coordination between member states in the management of clinical trials** and their respective Europeanisation, **pricing, access to innovative treatments**, among others. To this end, once again we are calling for better and clearer regulation not only at national level but also at European level. An innovative idea is the coordination of national ethics committees and a European ethics committee with decision-making and binding powers.

Finally, 3) the third block of measures focuses on the possibility of **utilising health data for research purposes as a secondary use**. This is a very important point which involves speeding up the implementation of the European Health Data Area and also, another essential point, the use of Artificial Intelligence which will be central to the health sector.

The "23andMe" case: The legal settlement that highlights the new challenges in terms of health and data protection

Also noteworthy is the California court's ruling on the class action lawsuit (an action that brings together several claims for compensation for mass damages) brought against 23andMe as a result of a security breach that led to the exposure of users' genetic data.

This lawsuit was filed in November 2023, based on the company's failure to guarantee the necessary mechanisms to protect this genetic data. This September, an agreement was reached between the parties, under which the company compensated users affected by the breach and was also obliged to increase the level of security monitored by regulatory bodies, legislators and consumers themselves.

Life Sciences Department



Ana Menéres
Partner, SRS Legal



José Doroana de Almeida
Associate, SRS Legal